Zobrazeno 1 - 10
of 94
pro vyhledávání: '"PCV20"'
Autor:
Shigeki Nakamura, Masashi Mikami, Tomoyuki Hayamizu, Naohiro Yonemoto, Camille Moyon, Mark Gouldson, Catriona Crossan, Jeffrey Vietri, Kazumasa Kamei
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 546-560 (2024)
Background The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden rem
Externí odkaz:
https://doaj.org/article/5239dd86e93040829e02bc8ac2bf6317
Autor:
Masayoshi Shinjoh, Kanae Togo, Tomoyuki Hayamizu, Naohiro Yonemoto, Junko Morii, Johnna Perdrizet, Kazumasa Kamei
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 485-497 (2024)
Background The Japanese National Immunization Program currently includes the pediatric 13 valent pneumococcal conjugate vaccine (PCV13) to prevent pneumococcal infections. We aimed to evaluate the cost-effectiveness of 20-valent PCV (PCV20) as a pedi
Externí odkaz:
https://doaj.org/article/71b05513c01b4d099126da3986cf1959
Publikováno v:
Vaccines, Vol 12, Iss 11, p 1279 (2024)
(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses are administered during the first year of life at 2, 4,
Externí odkaz:
https://doaj.org/article/80a73adcd0ab4c55b00f1901c00ebb59
Autor:
Min Huang, Jessica P. Weaver, Elamin Elbasha, Thomas Weiss, Natalie Banniettis, Kristen Feemster, Meghan White, Matthew S. Kelly
Publikováno v:
Vaccines, Vol 12, Iss 9, p 1045 (2024)
This study aimed to evaluate the cost-effectiveness of routine childhood immunization with the 20-valent pneumococcal conjugate vaccine (PCV20) in a four-dose regimen (3 + 1 schedule) versus the 15-valent PCV (PCV15/V114) in a three-dose regimen (2 +
Externí odkaz:
https://doaj.org/article/de7674a488e3451ebfcd4fe0e832ec3b
Autor:
Mikkelsen Malene B, Husby Oyvind, Molden Tor, Mwaura David N, Olsen Jens, Kristensen Nanna V, Vietri Jeffrey
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 21, Iss 1, Pp 1-15 (2023)
Abstract Background The morbidity and mortality of adult diseases caused by S. pneumoniae increase with age and presence of underlying chronic diseases. Currently, two vaccine technologies against S. pneumoniae are used: the 23-valent pneumococcal po
Externí odkaz:
https://doaj.org/article/3c350e411a46441d9fe8d353d49d3f86
Autor:
Michele Wilson, Cheryl McDade, Anna Trisia Beby-Heijtel, Angela Waterval-Overbeek, Vishalini Sundaram, Johnna Perdrizet
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 7, Pp 1809-1821 (2023)
Abstract Introduction The 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix) was introduced into the Dutch pediatric national immunization program (NIP) starting in 2011. However, there is substantial pneumococcal disease burden due to incre
Externí odkaz:
https://doaj.org/article/e4f2250be4154cf89e7baf3d8ac9eb14
Autor:
Johnna Perdrizet, Emily K. Horn, Kyla Hayford, Lindsay Grant, Rachid Barry, Liping Huang, Cheryl McDade, Michele Wilson
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 5, Pp 1351-1364 (2023)
Abstract Introduction This study estimates the annual population-level impact of 13-valent pneumococcal conjugate vaccine (PCV13) infant national immunization programs (NIPs) on vaccine-type and non-vaccine type invasive pneumococcal disease (IPD) in
Externí odkaz:
https://doaj.org/article/a02a168a132041509e51588b17b29c26
Publikováno v:
Expert Review of Vaccines, Vol 0, Iss 0 (2023)
Background The Belgian Superior Health Council (SHC) preferentially recommended the 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged ≥65 years, immunocompromised patients, and patients aged ≥50 years suffering from conditions that
Externí odkaz:
https://doaj.org/article/da02285529f54d06838c55ed009d888a
Autor:
Liping Huang, Cheryl L. McDade, Johnna E. Perdrizet, Michele R. Wilson, Sophie A. Warren, Susan Nzenze, Renilla Sewdas
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 3, Pp 933-950 (2023)
Abstract Introduction Pneumococcal disease, which presents a substantial health and economic burden, is prevented through pneumococcal vaccination programs. We assessed the impact of switching from a 13-valent-based (PCV13) to lower 10-valent-based (
Externí odkaz:
https://doaj.org/article/2621c9a97fcb4c118d30f699be4c6fda
Autor:
George Gourzoulidis, Myrto Barmpouni, Vasiliki Kossyvaki, Jeffrey Vietri, Charalampos Tzanetakos
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
ObjectiveHigher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent
Externí odkaz:
https://doaj.org/article/9eeacb46524d4f8dada9aed11373b463